23 March 2011
Chimerism in hand transplantation
Tobiasz Szajerka, Aleksandra Klimczak, Jerzy JableckiAnn Transplant 2011; 16(1): 83-89 :: ID: 881645
Abstract
Hand transplantation (HTx), a non-life saving reconstructive procedure, significantly improves the quality of life of upper limb amputees. However, HTx recipients need to take immunosuppressive drugs for the remainder of their lives and, despite dramatic improvements in the safety of modern immunosuppressive protocols, these patients continue to suffer from adverse effects, a fact which raises ethical doubts regarding the legitimacy of HTx given its non-life saving nature. Furthermore, the effectiveness of immunosuppressive treatment in preventing chronic rejection remains unclear. In order to circumvent these important impediments, the ultimate goal of composite tissue allografting (CTA) needs to be the induction of donor-specific tolerance. A possible way of attaining this objective may be chimerism, the coexistence in the host organism of 2 populations of cells of both donor and recipient origin. Clinical experiments of solid-organ transplant recipients and CTA research in animal models provide promising perspectives for establishing chimerism with the use of the facilitating cells and regulatory T-cells. This article reviews the available data on achieved chimerism in HTx and the relevant literature.
Keywords: hand transplant, Tolerance, Chimerism
In Press
Original article
Adipose Tissue Can Have a Protective Effect on Outcome After Simultaneous Pancreas–Kidney Transplantation i...Ann Transplant In Press; DOI: 10.12659/AOT.944518
Original article
Preoperative Evidence-Based Practice for Prevention of Early Postoperative Infections in Patients Receiving...Ann Transplant In Press; DOI: 10.12659/AOT.943610
Original article
Prediction of Renal Graft Function 1 Year After Adult Deceased-Donor Kidney Transplantation Using Variables...Ann Transplant In Press; DOI: 10.12659/AOT.944603
Original article
Impact of Donor-Recipient Relationship on Long-Term Outcomes in Living-Related Donor Kidney TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.945065
Most Viewed Current Articles
05 Apr 2022 : Original article 12,804
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 9,760
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,192
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,007
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860